|
08:00 – 08:30
08:00
|
08:30
|
Registration
|
|
|
08:30 – 08:35
08:30
|
08:35
|
Opening Remarks
|
|
|
08:35 – 10:40
08:35
|
10:40
|
MYELOPROLIFERATIVE NEOPLASMS
|
|
|
Moderators:
, ,
|
|
08:35 – 09:00
08:35
|
09:00
|
MPN Updates and the Evolution of the Diseases
|
|
|
09:00 – 09:20
09:00
|
09:20
|
The Myeloproliferative Neoplasms: Acquired Genetics and A Big Surprise
|
|
|
09:20 – 09:40
09:20
|
09:40
|
Genetic Heterogeneity & Rare Variants in MPN
|
|
|
09:40 – 10:00
09:40
|
10:00
|
Targeting the MPN Stem Cell and Molecular Response as a Surrogate for Survival
|
|
|
10:00 – 10:20
10:00
|
10:20
|
Panel Discussion
|
|
|
10:20 – 10:40
10:20
|
10:40
|
BREAK
|
|
|
10:40 – 13:00
10:40
|
13:00
|
MYELOFIBROSIS
|
|
|
Moderators:
, ,
|
|
10:40 – 11:00
10:40
|
11:00
|
Modern Management of Myelofibrosis
|
|
|
11:00 – 11:20
11:00
|
11:20
|
Clinical and Molecular Genetic Characterization of Myelofibrosis
|
|
|
11:20 – 11:40
11:20
|
11:40
|
Early Intervention in Myelofibrosis
|
|
|
11:40 – 00:00
11:40
|
00:00
|
Panel Discussion
|
|
|
12:00 – 13:00
12:00
|
13:00
|
LUNCH
|
|
|
13:00 – 15:00
13:00
|
15:00
|
POLYCYTHEMIA VERA
|
|
|
Moderators:
, ,
|
|
13:00 – 13:20
13:00
|
13:20
|
What's New in Polycythemia Vera
|
|
|
13:20 – 13:40
13:20
|
13:40
|
Early Intervention in Polycythemia Vera
|
|
|
13:40 – 14:00
13:40
|
14:00
|
Ropeg-IFN-α Selectively Suppresses JAK2 V617F Clones in PV Treatment
|
|
|
14:00 – 14:20
14:00
|
14:20
|
Predictors of Treatment Response in PV Treated with Ropeginterferon alfa-2b
|
|
|
14:20 – 14:40
14:20
|
14:40
|
Panel Discussion
|
|
|
14:40 – 15:00
14:40
|
15:00
|
BREAK
|
|
|
15:00 – 18:05
15:00
|
18:05
|
ESSENTIAL THROMBOCYTOSIS AND CLINICAL EXPERIENCE SHARING
|
|
|
Moderators:
, , , ,
|
|
15:00 – 15:20
15:00
|
15:20
|
Therapeutic Advances & Clinical Trials in ET
|
|
|
15:20 – 15:40
15:20
|
15:40
|
Real-World Experience: Prospective Ropeginterferon Alfa- 2b Therapy in PV & ET
|
|
|
15:40 – 16:00
15:40
|
16:00
|
From Dosing Strategy to Clinical Benefit: Rethinking Interferon Use Patterns to Optimize Efficacy and Safety
|
|
|
16:00 – 16:20
16:00
|
16:20
|
From Gene to Clinic: Translating Molecular Discoveries into Management Strategies in MPNs
|
|
|
16:20 – 16:40
16:20
|
16:40
|
BREAK
|
|
|
16:40 – 17:00
16:40
|
17:00
|
Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
|
|
|
17:00 – 17:20
17:00
|
17:20
|
Metformin Alleviates Side Effects and Supports the Resumption of Interferon Therapy in PV and ET
|
|
|
17:20 – 17:40
17:20
|
17:40
|
Myeloproliferative Neoplasm Subtype Impacts Risk of Incident Osteoporosis and Osteoporotic Fractures
|
|
|
17:40 – 18:00
17:40
|
18:00
|
Panel Discussion
|
|
|
18:00 – 18:05
18:00
|
18:05
|
Closing Remarks
|
|
